secwatch.observer — SEC 8-K summary
======================================

Issuer:     EyePoint, Inc. (EYPT)
CIK:        0001314102
Form:       8-K
Filed at:   2025-03-05T23:59:59+00:00
Accession:  0000950170-25-033065
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

EyePoint reports Q4 net loss $41.4M; DURAVYU Phase 3 enrollment ahead of expectations
--------------------------------------------------------------------------------

- Q4 net loss $41.4M ($0.64/share) vs $14.1M loss prior year; revenue $11.6M down from $14.0M.
- Full-year net loss $130.9M ($2.32/share) vs $70.8M loss prior year; revenue $43.3M vs $46.0M.
- DURAVYU Phase 3 wet AMD trials LUGANO (>50% enrolled) and LUCIA on track; enrollment completion H2 2025, topline data 2026.
- Phase 2 VERONA DME trial met endpoints: BCVA +10.3 letters vs +3.0 control; 43% had absence of DME.
- Cash $371M as of Dec 31, 2024; runway into 2027; no equity capital plans for 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1314102/000095017025033065/0000950170-25-033065-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1314102/000095017025033065/eypt-20250305.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-033065

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer